Impact of Minimal Residual Disease on Early Recurrence of Liver Metastatic Colorectal Cancer.

ABSTRACT: For patients with resectable colorectal liver metastases (CRLM), the efficacy of adjuvant chemotherapy remains a subject of debate. Several studies have concluded that postoperative circulating tumor DNA (ctDNA) is a marker of minimal residual disease (MRD) and is a useful prognostic factor in patients with nonmetastatic colorectal cancer. However, few studies have explored its application in cases involving metastases. This was an observational study that included CRLM patients who underwent primary and liver tumor resection. By examining targeted sequencing of 50 genes commonly mutated in CRC, we identified at least one somatic mutation in each patient's metastatic liver tumor. Blood samples were obtained before and 1-month after surgery. Fifty-three patients were included, and recurrenc

SUBMITTER: Kawashima M 

PROVIDER: S-EPMC12044645 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature